ICD-9 Code V76.44
Screening for malignant neoplasms of prostate
Not Valid for Submission
V76.44 is a legacy non-billable code used to specify a medical diagnosis of screening for malignant neoplasms of prostate. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
| ICD-9: | V76.44 |
| Short Description: | Scrn malig neop-prostate |
| Long Description: | Screening for malignant neoplasms of prostate |
Convert V76.44 to ICD-10
The following crosswalk between ICD-9 to ICD-10 is based based on the General Equivalence Mappings (GEMS) information:
- Z12.5 - Encounter for screening for malignant neoplasm of prostate
Code Classification
-
Supplementary classification of factors influencing health status and contact with health services (E)
-
Persons without reported diagnosis encountered during examination and investigation of individuals and populations (V70-V82)
- V76 Special screening for malignant neoplasms
-
Persons without reported diagnosis encountered during examination and investigation of individuals and populations (V70-V82)
Information for Medical Professionals
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-9 Code Edits are applicable to this code:
- Diagnoses for males only Diagnoses for males only
Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, this code applies to MALES only .
Index to Diseases and Injuries
References found for the code V76.44 in the Index of Diseases and Injuries:
- Screening for V82.9
- malignant neoplasm of V76.9
- prostate V76.44
- malignant neoplasm of V76.9
Information for Patients
Prostate Cancer Screening
What is cancer screening?
Cancer is a disease when the cells of the body grow out of control. Cancer screening is having tests to look for signs of cancer before you have any symptoms. By the time cancer causes symptoms, it may have already spread to other parts of your body. A screening test may help find cancer early, when it may be easier to treat.
Cancer screening only tells you whether you might have cancer. It doesn't diagnose cancer. If a screening test shows signs of cancer, you'll need to have other tests to find out if you do have cancer and how serious it may be.
What is prostate cancer screening?
Prostate cancer screening looks for signs of cancer in the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.
Prostate cancer is most common in people over age 50. It usually grows slowly and doesn't cause health problems. In fact, it's possible to live a long life with prostate cancer and never know you have it. But in certain cases, prostate cancer may spread to other parts of the body and can be very serious.
The goal of prostate cancer screening is to find prostate cancers that may be more likely to spread so they can be treated early.
What tests screen for prostate cancer?
Two tests are commonly used to screen for prostate cancer:
- A prostate-specific antigen test, also called a PSA blood test. PSA is a protein made by your prostate. A high level of PSA in your blood may mean you have prostate cancer, but it's not proof of cancer. That's because many other things may cause high PSA levels, including:
- Having an enlarged prostate (benign prostatic hyperplasia or BPH)
- Having other common prostate problems
- Taking certain medicines
In general, the higher your PSA, the more likely it is that you have cancer. But a low PSA blood level isn't a guarantee that you don't have cancer.
- Digital Rectal Examination (DRE). The DRE is a prostate exam. In this exam, your health care provider inserts a lubricated, gloved finger into your rectum to feel your prostate for lumps or anything unusual. A DRE can check only one side of the prostate.
A PSA test or a DRE may be able to detect prostate cancer at an early stage. But it is not clear whether early detection and treatment lower the risk of dying from prostate cancer. You should talk with your provider about the benefits and harms of prostate cancer screening.
What are the possible benefits and harms of prostate cancer screening?
The possible benefits of prostate cancer screening include:
- Finding and treating prostate cancer early before it spreads
- Getting a better sense of your prostate cancer risk (based on your PSA test)
- Peace of mind if your screening shows you're unlikely to have prostate cancer now
- The option to choose further testing and closely monitor your prostate if your screening shows you may have cancer
The possible harms of prostate cancer screening include:
- Getting a false positive result. This means that your PSA test shows you may have prostate cancer when you really don't. A false positive may lead to:
- Worry while you have more tests to look for signs of cancer.
- A prostate biopsy. In a biopsy, a doctor removes tissue from your prostate so it can be studied under a microscope to look for cancer cells. This is the only way to diagnose cancer. The possible harms of a prostate biopsy include:
- Fever
- Pain
- Blood in semen
- Urinary tract infection
- Having prostate cancer treatment that you may not have needed. Prostate cancer screening may lead to a cancer diagnosis, but it's not always clear whether the cancer is likely to grow and spread. You could have unnecessary treatment for cancer that would never have caused any health problems. And the common prostate cancer treatments may have serious, permanent complications, such as:
- Urinary incontinence
- Erectile dysfunction
- Problems controlling your bowel movements (BMs)
Should I be screened for prostate cancer?
Since there are benefits and risks to prostate screening, you should talk with your provider to decide if screening is right for you. You and your provider should consider:
- Your age. The risk of prostate cancer increases after age 50.
- Your family health history. If members of your family have had prostate cancer, your risk may be higher.
- Your race. Prostate cancer is more common in African Americans. They also have a higher risk of developing prostate cancer at a younger age and having more serious disease.
- Your general health. Are you well enough to have treatment for prostate cancer if it's found?
- What you prefer. How do you feel about the possible benefits and harms of screening, diagnosis, and treatment?
NIH: National Cancer Institute
[Read More]
ICD-9 Footnotes
General Equivalence Map Definitions
The ICD-9 and ICD-10 GEMs are used to facilitate linking between the diagnosis codes in ICD-9-CM and the new ICD-10-CM code set. The GEMs are the raw material from which providers, health information vendors and payers can derive specific applied mappings to meet their needs.
- Approximate Flag - The approximate flag is on, indicating that the relationship between the code in the source system and the code in the target system is an approximate equivalent.
- No Map Flag - The no map flag indicates that a code in the source system is not linked to any code in the target system.
- Combination Flag - The combination flag indicates that more than one code in the target system is required to satisfy the full equivalent meaning of a code in the source system.
Index of Diseases and Injuries Definitions
- And - The word "and" should be interpreted to mean either "and" or "or" when it appears in a title.
- Code also note - A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
- Code first - Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
- Type 1 Excludes Notes - A type 1 Excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
- Type 2 Excludes Notes - A type 2 Excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
- Includes Notes - This note appears immediately under a three character code title to further define, or give examples of, the content of the category.
- Inclusion terms - List of terms is included under some codes. These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- NEC "Not elsewhere classifiable" - This abbreviation in the Alphabetic Index represents "other specified". When a specific code is not available for a condition, the Alphabetic Index directs the coder to the "other specified” code in the Tabular List.
- NOS "Not otherwise specified" - This abbreviation is the equivalent of unspecified.
- See - The "see" instruction following a main term in the Alphabetic Index indicates that another term should be referenced. It is necessary to go to the main term referenced with the "see" note to locate the correct code.
- See Also - A "see also" instruction following a main term in the Alphabetic Index instructs that there is another main term that may also be referenced that may provide additional Alphabetic Index entries that may be useful. It is not necessary to follow the "see also" note when the original main term provides the necessary code.
- 7th Characters - Certain ICD-10-CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.
- With - The word "with" should be interpreted to mean "associated with" or "due to" when it appears in a code title, the Alphabetic Index, or an instructional note in the Tabular List. The word "with" in the Alphabetic Index is sequenced immediately following the main term, not in alphabetical order.